HRP20160005T1 - 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala - Google Patents

2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala Download PDF

Info

Publication number
HRP20160005T1
HRP20160005T1 HRP20160005TT HRP20160005T HRP20160005T1 HR P20160005 T1 HRP20160005 T1 HR P20160005T1 HR P20160005T T HRP20160005T T HR P20160005TT HR P20160005 T HRP20160005 T HR P20160005T HR P20160005 T1 HRP20160005 T1 HR P20160005T1
Authority
HR
Croatia
Prior art keywords
compound according
ethyl
fluorobenzyloxy
hydrogen
methoxyphenyl
Prior art date
Application number
HRP20160005TT
Other languages
English (en)
Inventor
Florian Thaler
Mauro Napoletano
Cibele Sabido-David
Ermanno Moriggi
Carla Caccia
Laura Faravelli
Alessandra Restivo
Patricia Salvati
Original Assignee
Newron Pharmaceuticals S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticals S.P.A. filed Critical Newron Pharmaceuticals S.P.A.
Publication of HRP20160005T1 publication Critical patent/HRP20160005T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Claims (21)

1. Spoj opće formule I [image] , naznačen time što: (a) J je skupina A-[(CH2)n-O]r- na položaju para u odnosu na lanac etilamino, gdje: n je 1; i r je 1; A je fenil supstituiran s fluorom kao skupinom; W je metoksi; R je vodik; R0 je vodik; R1 je vodik; (C1-C4)alkil; ciklopropilmetil; benzil; ili heterociklilmetil, gdje se heterociklilnu skupinu bira između furanila, tetrahidrofuranila i piridinila izborno supstituiranog s metoksi skupinom; R2 je vodik; (C1-C4)alkil; ili fenil; R3 je vodik; ili (C1-C4)alkil; i R4 je vodik; (C1-C4)alkil izborno supstituiran sa skupinom koju se bira između amino, dimetilamino i pirolidinila, gdje je pirolidinil izborno supstituiran s metilnom skupinom; ili R3 i R4, uzeti zajedno sa susjednim atomom dušika, tvore pirolidinilni ili morfolinilni prsten; ili (b) J je vodik; W je skupina A-[(CH2)n-O]r-, gdje: n je 1; r je 1; A je (C1-C4)alkil; ili fenil supstituiran s fluorom kao skupinom; R je vodik; R0 je vodik; R1 je furanilmetil; ili tetrahidrofuranilmetil; R2 je vodik; R3 je vodik; ili (C1-C4)alkil; i R4 je vodik; ili (C1-C4)alkil izborno supstituiran sa skupinom koju se bira između amino i dimetilamino; u slučaju kao bilo pojedinačni enantiomer ili dijastereoizomer ili njihova smjesa i njihove farmaceutski prihvatljive soli.
2. Spoj u skladu s patentnim zahtjevom 1, skupina (b), naznačen time što: J je vodik; W je skupina A-[(CH2)n-O]r-, gdje: n je 1; r je 1; A je (C1-C4)alkil; R je vodik; R0 je vodik; R1 je furanilmetil; ili tetrahidrofuranilmetil; R2 je vodik; R3 je vodik; ili (C1-C4)alkil; i R4 je (C1-C4)alkil; u slučaju kao bilo pojedinačni enantiomer ili dijastereoizomer ili njihova smjesa i njihove farmaceutski prihvatljive soli.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira između 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil]izobutilamino]-N-metilacetamida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil](tetrahidrofuran-3-ilmetil)amino]-N-metilacetamida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil]benzilamino]-N,N-dimetilacetamida; 2-[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etilamino]-N,N-dimetil-2-fenilacetamida; 2-[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etilamino]-1-(morfolin-4-il)-2-feniletanona; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil]benzilamino]-1-(pirolidin-1-il)etanona; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil]benzilamino]-N-(2-amino-2-metilpropil)acetamida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil]benzilamino]-N-(2-dimetilaminoetil)acetamida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil]benzilamino]-N-[2-(1-metilpirolidin-2-il)etil]acetamida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil](ciklopropilmetil)amino]-N-etilacetamida; 2-[[2-[3-(3-fluorbenziloksi)fenil]etil](furan-2-ilmetil)amino]-N-(2-dimetilaminoetil)acetamida; 2-[[2-[3-(3-fluorbenziloksi)fenil]etil](furan-2-ilmetil)amino]-N-(2-amino-2-metilpropil)acetamida; 2-[[2-[(3-butoksifenil)]etil](tetrahidrofuran-3-ilmetil)amino]-N,N-dimetilacetamida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil](ciklopropilmetil)amino]-N-metilacetamida; (S)-2-[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etilamino]-N-metil-4-metilvaleramida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil](furan-3-ilmetil)amino]-N-metilacetamida; 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil]benzilamino]-N-etilacetamida; i 2-[[2-[4-(3-fluorbenziloksi)-3-metoksifenil]etil](6-metoksipiridin-3-ilmetil)amino]-N-metilacetamida; u sučaju kao bilo pojedinačni enantiomer ili njihova smjesa i njihove farmaceutski prihvatljive soli.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je 2-[[2-(3-butoksifenil)etil](tetrahidrofuran-3-ilmetil)amino]-N,N-dimetilacetamid i njegove farmaceutski prihvatljive soli.
5. Spoj u skladu s patentnim zahtjevom 4, naznačen time što je pojedinačni enantiomer s [α]D = –10°, c = 0,1, MeOH (20 °C) ili pojedinačni enantiomer s [α]D = +10°, c = 0,1, MeOH (20 °C) ili njihova smjesa u bilo kojem omjeru i njihove farmaceutski prihvatljive soli.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je farmaceutski prihvatljiva sol hidroklorid.
7. Spoj u skladu s patentnim zahtjevom 6, naznačen time što je hidroklorid 2-[[2-(3-butoksifenil)etil](tetrahidrofuran-3-ilmetil)amino]-N,N-dimetilacetamida.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva od 1 do 7, naznačen time što je namijenjen upotrebi kao medikament aktivan kao modulator kalcijskih i/ili natrijskih kanala protiv poremećaja uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, poput neuropatske boli, kronične boli, akutne boli, glavobolja, neuroloških stanja, kognitivni i psihijatrijskih poremećaja, poput bipolarnih poremećaja, psihoze, anksioznosti i ovisnosti, upalnih procesa koji pogađaju bilo koji od tjelesnih sustava, poremećaja gastrointestinalnog sustava, poremećaja genitourinarnog sustava, bolesti očiju, bolesti jetre, kardiovaskularnih poremećaja i neurodegenerativnih poremećaja.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje neuropatske boli, kronične boli i/ili akutne boli.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje glavobolja, poput migrene.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje neuroloških stanja, poput epilepsije.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje kognitivnih i/ili psihijatrijskih poremećaja.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje poremećaja uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, poput upalnih procesa koji pogađaju bilo koji od tjelesnih sustava, poremećaja gastrointestinalnog sustava, poremećaja genitourinarnog sustava, bolesti očiju, bolesti jetre, kardiovaskularnih i/ili neurodegenerativnih poremećaja.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, namijenjen upotrebi kao medikament aktivan kao modulator kalcijskih i/ili natrijskih kanala protiv poremećaja uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, poput neuropatske boli, kronične boli, akutne boli, glavobolja, neuroloških stanja, kognitivni i psihijatrijskih poremećaja, poput bipolarnih poremećaja, psihoze, anksioznosti i ovisnosti, upalnih procesa koji pogađaju bilo koji od tjelesnih sustava, poremećaja gastrointestinalnog sustava, poremećaja genitourinarnog sustava, bolesti očiju, bolesti jetre, kardiovaskularnih poremećaja i neurodegenerativnih poremećaja, naznačen time što doza navedenog spoja djelotvorna u liječenju pacijenta koji boluje od bolesti uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala ne pokazuje bilo koju aktivnost inhibiranja MAO ili pokazuje znatno smanjenu aktivnost inhibiranja MAO.
16. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7 kao aktivni sastojak, uz farmaceutski prihvatljivu pomoćnu tvar.
17. Farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time što sadrži dodatno terapijsko sredstvo.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 4 do 7, naznačen time što je namijenjen upotrebi kao analgetik, antkonvulziv, antimanik i/ili antishizofrenik.
19. Spoj u skladu s bilo kojim od patentnih zahtjeva 4 do 7, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 18, gdje je farmaceutski prihvatljiva sol hidroklorid.
20. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 9 do 15 u liječenju pacijenata koji boluju od bolesti uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, gdje inhibiranje enzima MAO ne pomaže ili nuspojave inhibiranja MAO nameću negativna ograničenja.
21. Spoj u skladu s bilo kojim od patentnih zahtjeva 4 do 7, naznačen time što je namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 9 do 15, 18 i 19 u liječenju pacijenata koji boluju od bolesti uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, gdje inhibiranje enzima MAO ne pomaže ili nuspojave inhibiranja MAO nameću negativna ograničenja.
HRP20160005TT 2005-12-22 2016-01-04 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala HRP20160005T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05028147 2005-12-22
EP06829177.2A EP1963280B1 (en) 2005-12-22 2006-11-29 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
PCT/EP2006/011443 WO2007071311A1 (en) 2005-12-22 2006-11-29 2 -phenylethylamino derivatives as calcium and/or sodium channel modulators

Publications (1)

Publication Number Publication Date
HRP20160005T1 true HRP20160005T1 (hr) 2016-02-12

Family

ID=36178203

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160005TT HRP20160005T1 (hr) 2005-12-22 2016-01-04 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala

Country Status (26)

Country Link
US (3) US7855227B2 (hr)
EP (1) EP1963280B1 (hr)
JP (1) JP5271087B2 (hr)
KR (1) KR101380137B1 (hr)
CN (1) CN101309909B (hr)
AR (1) AR058720A1 (hr)
AU (1) AU2006329040C1 (hr)
BR (1) BRPI0620239B8 (hr)
CA (1) CA2629065C (hr)
CY (1) CY1117094T1 (hr)
DK (1) DK1963280T3 (hr)
ES (1) ES2556937T3 (hr)
HK (1) HK1124324A1 (hr)
HR (1) HRP20160005T1 (hr)
HU (1) HUE028329T2 (hr)
IL (1) IL191255A (hr)
IN (1) IN266803B (hr)
NO (1) NO341296B1 (hr)
NZ (1) NZ567540A (hr)
PL (1) PL1963280T3 (hr)
PT (1) PT1963280E (hr)
RS (1) RS54522B1 (hr)
RU (1) RU2397160C9 (hr)
SI (1) SI1963280T1 (hr)
TW (1) TWI379828B (hr)
WO (1) WO2007071311A1 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1658062T3 (da) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
RS54522B1 (en) * 2005-12-22 2016-06-30 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Modulators of Calcium and (or Sodium) Channels
PL2155663T3 (pl) 2007-06-15 2018-06-29 Newron Pharmaceuticals S.P.A. Podstawione pochodne 2-[2-(fenylo)etyloamino]alkanoamidu oraz ich zastosowanie jako modulatorów kanałów sodowych i (lub) wapniowych
EA019529B1 (ru) 2007-12-19 2014-04-30 Ньюрон Фармасьютикалс С.П.А. Альфа-аминоамидные производные, применяемые в лечении психиатрических расстройств
JP6116555B2 (ja) 2011-06-27 2017-04-19 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー フッ素化アリールアルキルアミノカルボキサミド誘導体
MX337469B (es) 2011-10-26 2016-03-02 Pfizer Ltd Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN106795098B (zh) 2014-10-02 2020-07-14 默加拜奥伍德有限公司 α-氨基酰胺衍生化合物及包含其的药物组合物
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
SG11202005361RA (en) 2017-12-14 2020-07-29 H Lundbeck As Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
EP3725768A1 (en) * 2019-04-17 2020-10-21 Newron Pharmaceuticals S.p.A. Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB586645A (en) * 1944-07-19 1947-03-26 Burroughs Wellcome Co Improvements relating to the synthesis of amino acid derivatives and salts thereof
GB1254332A (en) * 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
EP0625162B1 (en) * 1991-12-30 1998-05-13 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
FR2696934B1 (fr) 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
GB9500691D0 (en) * 1995-01-13 1995-03-08 Smithkline Beecham Plc Compounds
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
ATE293458T1 (de) * 1996-08-23 2005-05-15 Algos Pharm Corp Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
AU6144098A (en) 1997-02-14 1998-09-08 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
FR2760362B1 (fr) 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
US6117841A (en) * 1997-05-30 2000-09-12 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
DE19740110A1 (de) 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IT1295423B1 (it) * 1997-10-10 1999-05-12 Medivis S R L Uso della flunarizina nella terapia topica del glaucoma
ES2352739T3 (es) 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
WO1999055688A1 (en) * 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
SE9801494D0 (sv) 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
JP2002520286A (ja) 1998-07-09 2002-07-09 ワーナー−ランバート・カンパニー Ｇａｂａ類縁体及びカフェインを含んでなる組成物
KR20010071776A (ko) 1998-07-09 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 대상포진의 치료를 위한 ｇａｂａ 유사체 및항바이러스제를 포함하는 제약 조성물
US6316440B1 (en) * 1998-07-30 2001-11-13 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
WO2000053225A1 (en) 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
NZ514756A (en) * 1999-03-26 2004-04-30 Euro Celtique S Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
DK1169060T3 (da) 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
DE60034344T2 (de) 1999-07-22 2008-01-10 University Of Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
WO2001010381A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6472530B1 (en) * 1999-09-22 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
GB9930079D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
MXPA02009354A (es) * 2000-03-23 2004-05-14 Johnson & Johnson Tiepino[3,2-b]dihidropiridinas y composiciones y metodos relacionados.
CN1426397A (zh) 2000-03-31 2003-06-25 欧洲凯尔特股份有限公司 氨基吡啶类化合物及其作为抗惊厥剂和钠通道阻滞剂的应用
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
CA2413451A1 (en) 2000-06-19 2001-12-27 Merck Frosst Canada & Co. Methods of identifying gabab receptor subtype-specific agonists
FR2818978B1 (fr) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
SE0102858D0 (sv) 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
EP1423168B1 (en) * 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
US20050228017A1 (en) 2001-10-31 2005-10-13 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel anticancer compounds
US6897319B2 (en) 2001-12-27 2005-05-24 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl pyrrole heteroaryl methanones and methanols
EP1501804B1 (en) * 2002-04-26 2009-08-26 F. Hoffmann-La Roche Ag Isoquinoline derivatives mao-b inhibitors
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
CA2514574A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
US20040209960A1 (en) 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
WO2004087125A1 (en) 2003-04-02 2004-10-14 Ionix Pharmaceuticals Limited Amino acid derivatives as inhibitors of mammalian sodium channels
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
DK1658062T3 (da) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1535908A1 (en) * 2003-11-24 2005-06-01 Newron Pharmaceuticals S.p.A. N-acyl-N'-benzyl-alkylendiamino drivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ES2347581T3 (es) 2004-09-10 2010-11-02 Newron Pharmaceuticals S.P.A. Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
RS54522B1 (en) * 2005-12-22 2016-06-30 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Modulators of Calcium and (or Sodium) Channels

Also Published As

Publication number Publication date
NO20083237L (no) 2008-07-21
CA2629065A1 (en) 2007-06-28
KR101380137B1 (ko) 2014-04-11
HUE028329T2 (en) 2016-12-28
CN101309909B (zh) 2012-11-14
US20110046129A1 (en) 2011-02-24
ES2556937T3 (es) 2016-01-21
AU2006329040A1 (en) 2007-06-28
SI1963280T1 (sl) 2016-02-29
US8129427B2 (en) 2012-03-06
AU2006329040A2 (en) 2008-06-05
EP1963280B1 (en) 2015-10-28
TWI379828B (en) 2012-12-21
JP5271087B2 (ja) 2013-08-21
RU2397160C2 (ru) 2010-08-20
NO341296B1 (no) 2017-10-02
RU2397160C9 (ru) 2012-10-27
BRPI0620239A2 (pt) 2011-11-08
US8470877B2 (en) 2013-06-25
IN266803B (hr) 2015-06-03
PT1963280E (pt) 2016-02-02
CN101309909A (zh) 2008-11-19
WO2007071311A1 (en) 2007-06-28
BRPI0620239B1 (pt) 2020-10-06
CY1117094T1 (el) 2017-04-05
BRPI0620239B8 (pt) 2021-05-25
TW200745051A (en) 2007-12-16
US20120220592A1 (en) 2012-08-30
PL1963280T3 (pl) 2016-04-29
AR058720A1 (es) 2008-02-20
DK1963280T3 (en) 2015-12-14
RS54522B1 (en) 2016-06-30
AU2006329040C1 (en) 2011-12-08
US7855227B2 (en) 2010-12-21
KR20080081188A (ko) 2008-09-08
IL191255A (en) 2013-03-24
RU2008130045A (ru) 2010-01-27
AU2006329040B2 (en) 2011-07-28
US20080319057A1 (en) 2008-12-25
EP1963280A1 (en) 2008-09-03
JP2009521417A (ja) 2009-06-04
CA2629065C (en) 2013-08-06
HK1124324A1 (en) 2009-07-10
NZ567540A (en) 2010-07-30

Similar Documents

Publication Publication Date Title
HRP20160005T1 (hr) 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala
JP2009521417A5 (hr)
RU2007101685A (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
HRP20180324T1 (hr) Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala
JP2003503504A5 (hr)
HRP20100121T1 (hr) Derivati n-(aminoheteroaril)-1h-indol-2-karboksamida, njihovo dobivanje i terapijska primjena
HRP20140451T1 (hr) Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora
RS107504A (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
HRP20130942T1 (hr) Aminodiazepini kao modulatori toll-u sliäśnih receptora
WO1999031074A3 (en) ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
WO2004066987B1 (en) Use of sodium channel modulators for treating gastrointestinal tract disorders
CA2512683A1 (en) Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy
RU2003128992A (ru) Омега-аминоалкиламиды r-2-арилпропионовых кислот в качестве ингибиторов хемотаксиса полиморфноядерных и одноядерных клеток
NZ603724A (en) Piperidine derivatives and their use for the treatment of metabolic disorders
RU2002125495A (ru) Гидроксифенил-пиперидин-4-илиден-метил-бензамидные производные для лечения боли
HRP20121078T1 (hr) Farmaceutski sastav za lijeäśenje hiperaktivnog mjehura
RU2004139050A (ru) Производные 1-сульфонил-4-аминоалкоксииндола в качестве модуляторов 5-нт6 рецептора для лечения заболеваний цнс
RU2010143452A (ru) Замещенные циклогексилдиамины
JP2010529969A5 (hr)
HRP20130989T1 (hr) (2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže
JP2012520321A5 (hr)
US20210198218A1 (en) Compounds for therapeutic use
RU2001104890A (ru) Соединения N,N-замещенного циклического амина